Vânia Oliveira Carvalho
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Vânia Oliveira Carvalho has a total of 210 co-authors. Here are the top co-authors by number of shared publications:
- Kerstin Taniguchi Abagge
Universidade Federal do Paraná, Brazil
27 shared publications Leide Parolin Marinoni
23 shared publications- Renata Robl
Division of Pediatric Dermatology, Department of Pediatrics, Federal University of Paraná, Hospital de Clínicas da UFPR, Curitiba, Paraná, Brazil
19 shared publications - Mariana Aparecida Pasa Morgan
Faculdade Ceres
13 shared publications Betina Werner
Pathology Division Federal University of Paraná (UFPR) Curitiba Brazil
12 shared publicationsMarjorie Uber
Department of Pediatric, Federal University of Paraná (UFPR), Curitiba, Paraná, Brazil
12 shared publications
Latest Publications
- 23 January 2026
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 45 (7) , e249-e252
Challenges and Solutions in Managing Umbilical Myiasis With Sepsis in a Newborn
Background: Myiasis is caused by the infestation of fly larvae and occurs more frequently in tropical, rural and low socioeconomic areas. We report a rare case of umbilical myiasis in a neonate, complicated by sepsis caused by Staphylococcus aureus . Case report: The patient, born in a vulnerable family, presented on the fourth day of life with erythema in the umbilical region, accompanied by serous drainage and visible larvae. Immobilization and manual removal of the larvae were attempted 3 times but proved ineffective. On the 10th day of hospitalization, oral ivermectin (200 μg/kg) was administered. Two days after initiating the medication, no larvae were observed, and no adverse events occurred. The delay in initiating treatment, due to insufficient robust evidence of ivermectin’s safety in children weighing less than 15 kg, contributed to complications and prolonged hospitalization. Discussion: Umbilical myiasis reflects inadequate hygiene conditions and socioeconomic vulnerability. Traditional management in children under 15 kg includes occlusion with Vaseline or similar substances and mechanical removal of the larvae. This report emphasizes the critical need for safety studies on ivermectin’s use in children weighing less than 15 kg, considering its potential to significantly improve the management of neglected parasitic diseases.
- 23 January 2026
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 45 (7) , e249-e252
Challenges and Solutions in Managing Umbilical Myiasis With Sepsis in a Newborn
Background: Myiasis is caused by the infestation of fly larvae and occurs more frequently in tropical, rural and low socioeconomic areas. We report a rare case of umbilical myiasis in a neonate, complicated by sepsis caused by Staphylococcus aureus . Case report: The patient, born in a vulnerable family, presented on the fourth day of life with erythema in the umbilical region, accompanied by serous drainage and visible larvae. Immobilization and manual removal of the larvae were attempted 3 times but proved ineffective. On the 10th day of hospitalization, oral ivermectin (200 μg/kg) was administered. Two days after initiating the medication, no larvae were observed, and no adverse events occurred. The delay in initiating treatment, due to insufficient robust evidence of ivermectin’s safety in children weighing less than 15 kg, contributed to complications and prolonged hospitalization. Discussion: Umbilical myiasis reflects inadequate hygiene conditions and socioeconomic vulnerability. Traditional management in children under 15 kg includes occlusion with Vaseline or similar substances and mechanical removal of the larvae. This report emphasizes the critical need for safety studies on ivermectin’s use in children weighing less than 15 kg, considering its potential to significantly improve the management of neglected parasitic diseases.
- 28 November 2025
- Published by Wiley in International Journal of Dermatology
- Vol. 65 (6) , 1225-1230
Development of the AAcQLI : A New Instrument for Assessing Quality of Life in Children With Alopecia Areata
Background: Alopecia areata (AA) is a chronic inflammatory disease characterized by non‐scarring hair loss, which can markedly affect the quality of life (QoL) of children. The absence of disease‐specific instruments to measure this impact motivated the development of the Alopecia Areata Children's Quality of Life Index (AAcQLI). Methods: This study aims to develop and validate a disease‐specific instrument to assess QoL in children with AA, addressing emotional, social, and functional domains. The AAcQLI was developed through a review of existing instruments, refined by an expert committee, and tested in a pilot sample. Its psychometric properties were evaluated by examining content and construct validity, while reliability was assessed through test–retest and internal consistency using Cronbach's α coefficient. Results: The study sample comprised 20 children, with a median age of 9.5 years (interquartile range [IQR] = 7.5–13). The AAcQLI demonstrated good internal consistency (Cronbach's α = 0.86) and excellent content validity (Content Validity Index = 1.0). Convergent validity indicated fair agreement with the Children's Dermatology Life Quality Index (CDLQI) ( k = 0.24) and slight agreement, as measured by the Severity of Alopecia (SALT) ( k = 0.08). Conclusion: The AAcQLI is a promising tool for assessing quality of life in children with AA. Further studies with larger and more diverse populations are warranted to refine its measurement properties and strengthen its clinical applicability in evaluating the psychosocial impact of the disease.
- 28 November 2025
- Published by Wiley in International Journal of Dermatology
- Vol. 65 (6) , 1225-1230
Development of the AAcQLI : A New Instrument for Assessing Quality of Life in Children With Alopecia Areata
Background: Alopecia areata (AA) is a chronic inflammatory disease characterized by non‐scarring hair loss, which can markedly affect the quality of life (QoL) of children. The absence of disease‐specific instruments to measure this impact motivated the development of the Alopecia Areata Children's Quality of Life Index (AAcQLI). Methods: This study aims to develop and validate a disease‐specific instrument to assess QoL in children with AA, addressing emotional, social, and functional domains. The AAcQLI was developed through a review of existing instruments, refined by an expert committee, and tested in a pilot sample. Its psychometric properties were evaluated by examining content and construct validity, while reliability was assessed through test–retest and internal consistency using Cronbach's α coefficient. Results: The study sample comprised 20 children, with a median age of 9.5 years (interquartile range [IQR] = 7.5–13). The AAcQLI demonstrated good internal consistency (Cronbach's α = 0.86) and excellent content validity (Content Validity Index = 1.0). Convergent validity indicated fair agreement with the Children's Dermatology Life Quality Index (CDLQI) ( k = 0.24) and slight agreement, as measured by the Severity of Alopecia (SALT) ( k = 0.08). Conclusion: The AAcQLI is a promising tool for assessing quality of life in children with AA. Further studies with larger and more diverse populations are warranted to refine its measurement properties and strengthen its clinical applicability in evaluating the psychosocial impact of the disease.
- 23 October 2025
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 14 (1) , 283-285.e1
Burden of childhood cutaneous mastocytosis: Severity and caregivers’ quality of life
- 23 October 2025
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 14 (1) , 283-285.e1
Burden of childhood cutaneous mastocytosis: Severity and caregivers’ quality of life
- Open Access
- 19 September 2025
- Published by Springer Nature in American Journal of Clinical Dermatology
- Vol. 26 (6) , 1031-1043
Systemic Treatments in Moderate-to-Severe Atopic Dermatitis in Pediatric Patients up to 12 Years of Age: Real-World Treatment Outcomes from the PEDISTAD Registry
Background Atopic dermatitis (AD), a chronic systemic disease, can cause intense skin itching and negatively impact sleep, mood, and quality of life (QoL) for patients and families. Methods PEDISTAD is an ongoing, 10-year, observational registry describing disease characteristics, atopic comorbidities, and treatment patterns in pediatric patients (aged <12 years at enrollment) with moderate-to-severe AD. This 3-year interim analysis evaluates clinician-reported and caregiver-reported/patient-reported outcomes (Eczema Area and Severity Index [EASI], percent body surface area affected, worst itching/scratching, Children’s Dermatology Life Quality Index, and Dermatitis Family Impact) in children treated with dupilumab, methotrexate, and/or cyclosporine. Outcomes were assessed as change from therapy start to last observation (either data cutoff date or treatment discontinuation). Results Mean (±SE) EASI scores at the time of the last 3-year interim observation were consistent with mild disease in the dupilumab cohort and moderate disease in the methotrexate and cyclosporine cohorts. Improvements in pruritus were numerically greater in the dupilumab cohort relative to the methotrexate and cyclosporine cohorts, while improvements in QoL were similar in the dupilumab and methotrexate cohorts, with no significant change in the cyclosporine cohort. Rates of AD exacerbation were numerically lower with dupilumab treatment relative to methotrexate treatment which were numerically lower than cyclosporine treatment. Dupilumab discontinuation rates were numerically lower relative to methotrexate which were numerically lower than cyclosporine. Conclusions This PEDISTAD 3-year interim analysis of dupilumab, methotrexate, and cyclosporine treatment in children with AD demonstrates numerically greater improvements in AD signs, symptoms and QoL with dupilumab treatment relative to methotrexate and cyclosporine [Video abstract and graphical abstract available]. Clinical Trial Registration NCT03687359. Graphical abstract Video abstract Supplementary file1 (MP4 58163 KB)
- 19 September 2025
- Published by Springer Nature in American Journal of Clinical Dermatology
- Vol. 26 (6) , 1031-1043
Open AccessSystemic Treatments in Moderate-to-Severe Atopic Dermatitis in Pediatric Patients up to 12 Years of Age: Real-World Treatment Outcomes from the PEDISTAD Registry
Background Atopic dermatitis (AD), a chronic systemic disease, can cause intense skin itching and negatively impact sleep, mood, and quality of life (QoL) for patients and families. Methods PEDISTAD is an ongoing, 10-year, observational registry describing disease characteristics, atopic comorbidities, and treatment patterns in pediatric patients (aged <12 years at enrollment) with moderate-to-severe AD. This 3-year interim analysis evaluates clinician-reported and caregiver-reported/patient-reported outcomes (Eczema Area and Severity Index [EASI], percent body surface area affected, worst itching/scratching, Children’s Dermatology Life Quality Index, and Dermatitis Family Impact) in children treated with dupilumab, methotrexate, and/or cyclosporine. Outcomes were assessed as change from therapy start to last observation (either data cutoff date or treatment discontinuation). Results Mean (±SE) EASI scores at the time of the last 3-year interim observation were consistent with mild disease in the dupilumab cohort and moderate disease in the methotrexate and cyclosporine cohorts. Improvements in pruritus were numerically greater in the dupilumab cohort relative to the methotrexate and cyclosporine cohorts, while improvements in QoL were similar in the dupilumab and methotrexate cohorts, with no significant change in the cyclosporine cohort. Rates of AD exacerbation were numerically lower with dupilumab treatment relative to methotrexate treatment which were numerically lower than cyclosporine treatment. Dupilumab discontinuation rates were numerically lower relative to methotrexate which were numerically lower than cyclosporine. Conclusions This PEDISTAD 3-year interim analysis of dupilumab, methotrexate, and cyclosporine treatment in children with AD demonstrates numerically greater improvements in AD signs, symptoms and QoL with dupilumab treatment relative to methotrexate and cyclosporine [Video abstract and graphical abstract available]. Clinical Trial Registration NCT03687359. Graphical abstract Video abstract Supplementary file1 (MP4 58163 KB)
- 18 April 2025
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 317 (1) , 1-3
Frequency of sleep disturbances and signs of attention deficit and hyperactivity disorder in schoolchildren with atopic dermatitis
- 18 April 2025
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 317 (1) , 1-3
Frequency of sleep disturbances and signs of attention deficit and hyperactivity disorder in schoolchildren with atopic dermatitis
- 12 February 2025
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 317 (1) , 1-3
Circle hair and pigtail hair at newborn skin - a new transient sign
- 12 February 2025
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 317 (1) , 1-3
Circle hair and pigtail hair at newborn skin - a new transient sign
- Open Access
- 9 December 2024
- Published by Elsevier in Jornal de Pediatria
- Vol. 101 (2) , 276-281
Cloth versus disposable diapers: an exploratory study on family habits
- 9 December 2024
- Published by Elsevier in Jornal de Pediatria
- Vol. 101 (2) , 276-281
Open AccessCloth versus disposable diapers: an exploratory study on family habits
- 29 November 2024
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 317 (1) , 1-8
Adapting pediatric dermatology textbooks in South America: enhancing visual representation for skin of color patients
Skin diseases have different visual characteristics in skin of color, making recognition a challenge. Pictures and illustrations of darker skin tones in the literature are scarce. In American pediatric dermatology books, less than 40% of photographs depict skin of color. No similar studies have been conducted for South American pediatric dermatology books. This study evaluates the frequency of photographs of skin of color in pediatric dermatology textbooks and atlases. A prospective documentary study was conducted on the skin color of clinical photographs from 5 pediatric dermatology books (4 Brazilian, 1 Argentinian). All photographs were evaluated by three researchers and classified using the Massey-Martin scale (white 1–2, light brown 3–5, dark brown 6–8, black 9–10). Out of 3,471 photographs, 1,000 were excluded, and skin color was determined in 2,471 photographs. White was identified in 1,403 (56%), light brown in 1,044 (42%), dark brown in 24 (1%), and 0 (0%) in black. Atopic dermatitis, contact dermatitis, and psoriasis were the most common diagnoses; however, no dark brown or black skin was represented. In conclusion, photographs of skin of color were less frequent, despite most of the Brazilian population (55.5%) identifying as Black, and in Argentina, 0.7%, though hindered by the lack of self-identification questions before the 2022 census. This disparity undermines education, highlighting the need to increase representation of skin of color in educational materials to improve healthcare for these populations.
- 29 November 2024
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 317 (1) , 1-8
Adapting pediatric dermatology textbooks in South America: enhancing visual representation for skin of color patients
Skin diseases have different visual characteristics in skin of color, making recognition a challenge. Pictures and illustrations of darker skin tones in the literature are scarce. In American pediatric dermatology books, less than 40% of photographs depict skin of color. No similar studies have been conducted for South American pediatric dermatology books. This study evaluates the frequency of photographs of skin of color in pediatric dermatology textbooks and atlases. A prospective documentary study was conducted on the skin color of clinical photographs from 5 pediatric dermatology books (4 Brazilian, 1 Argentinian). All photographs were evaluated by three researchers and classified using the Massey-Martin scale (white 1–2, light brown 3–5, dark brown 6–8, black 9–10). Out of 3,471 photographs, 1,000 were excluded, and skin color was determined in 2,471 photographs. White was identified in 1,403 (56%), light brown in 1,044 (42%), dark brown in 24 (1%), and 0 (0%) in black. Atopic dermatitis, contact dermatitis, and psoriasis were the most common diagnoses; however, no dark brown or black skin was represented. In conclusion, photographs of skin of color were less frequent, despite most of the Brazilian population (55.5%) identifying as Black, and in Argentina, 0.7%, though hindered by the lack of self-identification questions before the 2022 census. This disparity undermines education, highlighting the need to increase representation of skin of color in educational materials to improve healthcare for these populations.
- 30 October 2024
- Published by Springer Nature in Indian Journal of Pediatrics
- Vol. 92 (2) , 193-194
Chikungunya: Atypical Dermatological Findings in an Infant
- 30 October 2024
- Published by Springer Nature in Indian Journal of Pediatrics
- Vol. 92 (2) , 193-194
Chikungunya: Atypical Dermatological Findings in an Infant
- 30 August 2024
- Published by Oxford University Press (OUP) in Medical Mycology
- Vol. 62 (9)
Molecular analysis of cutaneous yeast isolates in the mycobiota of children with atopic dermatitis
The skin of patients with atopic dermatitis (AD) has a greater diversity of mycobiota. An observational, prospective, cross-sectional, analytical, and comparative study was conducted involving 80 patients with AD (ADG) and 50 individuals without AD (wADG) in a tertiary hospital in Brazil. Skin scale samples were collected from the frontal, cervical, fossae cubital, and popliteal regions and identified using molecular biology techniques. The results showed that 47.5% of ADG had identified yeasts compared to 0% of wADG (p < 0.001). The yeasts Rhodotorula mucilaginosa and Candida parapsilosis were the most abundant. The probability of colonization increased with age, showing values of 40% at 60 months and 80% at 220 months (p = 0.09). The cervical region (12.5%) was colonized to the greatest extent. Our findings revealed that positive mycology was not more probable when the SCORAD or EASI value increased (p = 0.23 and 0.53, respectively). The results showed that the sex, age, and different population types directly affected the composition of the mycobiota in the population analyzed. A higher frequency of colonization and greater diversity of yeast species were detected in the cutaneous mycobiota of children with AD. Atopic dermatitis (AD) is a skin disease which can be colonized by microorganisms. We evaluated patients with and without the disease and found a higher frequency of colonization by Rhodotorula mucilaginosa and Candida parapsilosis on the skin of children with AD.
- 30 August 2024
- Published by Oxford University Press (OUP) in Medical Mycology
- Vol. 62 (9)
Molecular analysis of cutaneous yeast isolates in the mycobiota of children with atopic dermatitis
The skin of patients with atopic dermatitis (AD) has a greater diversity of mycobiota. An observational, prospective, cross-sectional, analytical, and comparative study was conducted involving 80 patients with AD (ADG) and 50 individuals without AD (wADG) in a tertiary hospital in Brazil. Skin scale samples were collected from the frontal, cervical, fossae cubital, and popliteal regions and identified using molecular biology techniques. The results showed that 47.5% of ADG had identified yeasts compared to 0% of wADG (p < 0.001). The yeasts Rhodotorula mucilaginosa and Candida parapsilosis were the most abundant. The probability of colonization increased with age, showing values of 40% at 60 months and 80% at 220 months (p = 0.09). The cervical region (12.5%) was colonized to the greatest extent. Our findings revealed that positive mycology was not more probable when the SCORAD or EASI value increased (p = 0.23 and 0.53, respectively). The results showed that the sex, age, and different population types directly affected the composition of the mycobiota in the population analyzed. A higher frequency of colonization and greater diversity of yeast species were detected in the cutaneous mycobiota of children with AD. Atopic dermatitis (AD) is a skin disease which can be colonized by microorganisms. We evaluated patients with and without the disease and found a higher frequency of colonization by Rhodotorula mucilaginosa and Candida parapsilosis on the skin of children with AD.